The Efficacy of Neostigmine as an adjuvant to Hyperbaric Prilocaine 2% for intrathecal Block in Reducing the incidence and severity of Post Dural Puncture Headache after Cesarean Section .

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202412678145639

Enrollment

140

Registered

2024-12-23

Start date

2023-06-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

Prilocaine Only

Neostigmine added to Prilocaine

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ASA physical status of I or II . 2. Elective caesarean section under spinal anesthesia. 3. Age group 18-45 years old

Exclusion criteria

Exclusion criteria: 1. Patient Refusal . 2. Infection at site of injection. 3. Hypovolemia. 4. Increased intracranial pressure. 5. Coagulopathy 6. Severe mitral or aortic stenosis. 7. Allery to drugs used . 8. Any drug abuse . 9. A history of chronic pain, Migraine, cluster headache . 10. Digestive problems with nausea and vomiting 11. Cognitive or memory disorders. 12. ASA lll and lV

Design outcomes

Primary

Measure	Time frame
The efficacy of Neostigmine as adjuvant to hyperbaric Prilocaine in intrathecal block in reducing incidence and severity of post puncture Dural headache after cesarian section .	—

Secondary

Measure	Time frame
Hemodynamic effects including MAP and Heart rate of adding Neostigmine to Prilocaine in intrathecal injection	—

Countries

Egypt

Contacts

Public ContactLoay;Noha Ashraf;Elsharnouby

Assistant Lecturer Department of Anesthesia Faculty of Medicine Ain Shams University ;Professor of Anesthesia Faculty of Medicine Ain Shams University

loay.ashraf@med.asu.eg;nmelsharnouby@med.asu.eg01097665767;01001518633

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026